• <em>Crbn</em> ^I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
• ABCDXXX: The obscenity of postmarketing surveillance for teratogenic effects
• AGA Clinical Practice Update on Pregnancy-Related Gastrointestinal and Liver Disease: Expert Review
• Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
• Crbn (I391V) is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
• Embryo-fetal exposure and developmental outcome of lenalidomide following oral administration to pregnant cynomolgus monkeys
• Genetic Syndromes, Maternal Diseases and Antenatal Factors Associated with Autism Spectrum Disorders (ASD)
• Haemoglobin F modulation in childhood sickle cell disease
• Health-related quality of life after 50 years in individuals with thalidomide embryopathy: Evidence from a German cross-sectional survey
• Human teratogens and genetic phenocopies. Understanding pathogenesis through human genes mutation
• Integrative Role of the SALL4 Gene: From Thalidomide Embryopathy to Genetic Defects of the Upper Limb, Internal Organs, Cerebral Midline, and Pituitary
• No, not more talk about Duane syndrome
• Oxidative DNA damage and repair in teratogenesis and neurodevelopmental deficits
• Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019
• Recognition of the phenotype of thalidomide embryopathy in countries endemic for leprosy: new cases and review of the main dysmorphological findings
• Thalidomide and misoprostol: Ophthalmologic manifestations and associations both expected and unexpected
• Thalidomide has anti-inflammatory properties in neonatal immune cells
• Thromboembolism and congenital malformations: from Duane syndrome to thalidomide embryopathy